The MCM protein family is a core component of DNA replication licensing and replication origin activation. MCM2, MCM3, MCM4, MCM5, MCM6, and MCM7 jointly form the MCM2-7 complex, which is loaded onto replication origins in G1 phase and forms the CMG helicase with CDC45 and GINS in S phase, participating in replication fork progression.

Keywords: MCM proteins; MCM2-7 complex; DNA replication licensing; pre-replication complex; CMG helicase; replication fork; replication stress; cell cycle; tumor proliferation; DNA damage response

1 Positioning of MCM Proteins and Boundaries of Replication Licensing

1.1 MCM2-7 Complex and Replication Origin Licensing

Eukaryotic DNA replication must ensure that each replication origin is initiated only once within a single cell cycle. Loading of the MCM2-7 complex is a key step by which a replication origin becomes licensed. In G1 phase, the ORC complex recognizes replication origins, while CDC6 and CDT1 assist in loading MCM2-7 onto chromatin to form the pre-replication complex. After cells enter S phase, some licensed origins are activated under the regulation of CDK and DDK and further form the CMG helicase. The core significance of MCM protein detection is to determine whether cells have entered a replication-ready state, rather than simply judging whether cells are in a proliferative background.

1.2 Boundaries Between MCM Proteins, Ki-67, PCNA, and EdU Detection

MCM proteins are located upstream in the DNA replication program and mainly reflect replication licensing and replication potential. Ki-67 mainly reflects whether cells are within the proliferative cell cycle. PCNA is closer to DNA replication elongation and DNA repair. EdU/BrdU directly labels newly synthesized DNA. In actual research, MCM proteins should not replace Ki-67, PCNA, or EdU, but should be combined according to the experimental purpose. When analyzing replication licensing, MCM should be evaluated together with CDC6/CDT1. When analyzing S-phase replication, EdU and PCNA should be included. When analyzing replication stress, indicators such as RPA, p-Chk1 (Ser317/Ser345), and γH2AX should be added.

2 Pre-Replication Complex and MCM Loading Mechanism

2.1 ORC-CDC6-CDT1 and MCM Loading

Replication licensing begins with ORC complex binding to replication origins. CDC6 and ORC jointly build the licensing platform, while CDT1 is responsible for delivering MCM2-7, enabling MCM2-7 to be loaded onto DNA and enter a standby state for activation. This mechanism divides DNA replication control into two levels: in G1 phase, replication origins are allowed to acquire initiation competence; in S phase, only some of these origins are selected for actual activation, thereby reducing the risk of re-replication of the same DNA region within one cell cycle.

2.2 MCM Double Hexamer and the Licensed State

After MCM2-7 is loaded onto DNA, it can form a head-to-head double hexamer structure, which is an important basis for replication origin licensing. This state does not mean that replication has already started, but indicates that the origin has acquired the conditions for later activation. If only total MCM expression is detected, “enhanced replication licensing” can easily be misinterpreted as “enhanced DNA replication.” A more reasonable strategy is to distinguish total MCM, chromatin-bound MCM, and CMG-associated MCM. Chromatin-bound MCM is closer to replication licensing, while the simultaneous presence of MCM with CDC45/GINS is closer to replication origin activation.

2.3 CDT1-Geminin Axis and Restriction of Re-Replication

MCM2-7 loading mainly occurs from mitotic exit through G1 phase and is suppressed after entry into S phase. After entry into S phase, if new MCM2-7 continues to be loaded, cells may undergo re-replication, causing DNA damage and genomic instability. CDT1 is an important factor for MCM loading, while Geminin can inhibit CDT1 and prevent re-licensing during S and G2 phases. Therefore, in cell cycle or drug intervention experiments, if re-replication, licensing abnormality, or G1/S dysregulation is suspected, CDC6, CDT1, Geminin, Cyclin E/CDK2, p21, and DNA content should be evaluated together.

3 CMG Helicase and Replication Fork Progression

3.1 CDK/DDK and Replication Origin Activation

After cells enter S phase, new replication licensing is no longer allowed. Instead, previously loaded MCM2-7 is activated. DDK promotes phosphorylation of the MCM complex, and CDK regulates replication origin initiation-related factors. CDC45 and GINS are then recruited to MCM2-7 to form the active CMG complex. This process indicates that MCM loading and replication origin activation are not the same event: MCM loading represents licensing, while CMG formation indicates that a replication origin has entered the activation stage.

3.2 CDC45-GINS-MCM and the CMG Complex

The CMG complex is the core helicase structure in replication fork progression. MCM2-7 provides the helicase core, while CDC45 and GINS participate in activation and stabilization of the replication fork. Only after CMG formation does the MCM system truly enter the replication fork progression stage. Increased expression of a single MCM member cannot be equated with enhanced CMG activity, nor can it demonstrate that DNA replication is progressing smoothly. If the research goal is to determine whether replication origins are activated, CDC45, GINS, chromatin-bound MCM, and EdU incorporation should be assessed rather than only observing changes in total protein level of one MCM protein.

3.3 PCNA, DNA Polymerase, and Replication Elongation

CMG is responsible for opening the DNA double helix, while PCNA functions as the sliding clamp of DNA polymerase during replication elongation. MCM and PCNA represent different levels of the same replication process. MCM is positioned more upstream and represents licensing and origin activation, whereas PCNA is positioned more downstream and reflects replication elongation and DNA repair. Therefore, increased MCM with unchanged PCNA may indicate enhanced replication preparation without enhanced elongation. Increased PCNA without obvious MCM changes may suggest that changes in replication elongation or repair processes are more prominent.

4 MCM Licensing Reserve and Replication Stress

4.1 Dormant Replication Origins and MCM Licensing Reserve

The amount of MCM2-7 loaded in cells is usually greater than the amount required for replication initiation under normal conditions. Some licensed replication origins do not initiate immediately, but are retained as dormant origin reserves. When replication forks are blocked, replication speed decreases, or local DNA regions are difficult to replicate, backup origins can be activated to help cells complete genome replication. This is also a key reason why MCM results are easily misinterpreted. Increased MCM does not necessarily represent enhanced DNA replication; it may also represent increased licensing reserve. Decreased MCM does not necessarily cause an immediate decrease in EdU, because cells may still retain a certain backup licensing capacity.

4.2 Oncogene Activation and Replication Fork Blockage

Oncogene activation can drive cells to excessively enter the replication program, causing abnormal replication origin firing, increased replication fork burden, and replication stress. Under these conditions, MCM proteins may increase, but this increase should not be simply interpreted as enhanced proliferation. It is also necessary to determine whether RPA, p-Chk1 (Ser317/Ser345), or γH2AX increases at the same time. If MCM elevation is accompanied by increased replication stress indicators, it more likely indicates replication fork blockage, single-stranded DNA exposure, and DNA damage response after excessive activation of the replication program.

4.3 Combined Interpretation of MCM, RPA, p-Chk1 (Ser317/Ser345), and γH2AX

MCM proteins should be interpreted within the chain of “replication licensing-DNA synthesis-replication stress.” Increased MCM expression with increased EdU indicates that MCM expression and DNA synthesis activity are both elevated; whether replication licensing is enhanced requires assessment of chromatin-bound MCM2-7. Increased MCM expression without increased EdU indicates increased MCM expression without a corresponding increase in DNA synthesis and does not by itself establish enhanced replication licensing or replication preparation. Increased MCM accompanied by increased RPA, p-Chk1 (Ser317/Ser345), or γH2AX more strongly supports replication stress or DNA damage response rather than simple proliferation enhancement.

5 MCM Proteins and Tumor Proliferation Research

5.1 Enhanced Replication Licensing and Tumor Cell Proliferation

Tumor cells often show sustained proliferation, enhanced replication licensing, imbalanced cell cycle checkpoints, and increased replication stress. Expression of MCM2, MCM5, MCM7, and other members can assist in evaluating proliferative and replication potential in tumor cells, but cannot independently assess replication origin activity. Compared with Ki-67, MCM is more biased toward replication licensing. Compared with PCNA, MCM is more biased toward pre-initiation preparation. Therefore, MCM proteins are suitable as mechanistic indicators of abnormal tumor replication programs, and should not be described as tumor-specific diagnostic markers.

5.2 Therapeutic Intervention and Replication Inhibition

DNA-damaging drugs, radiotherapy, CDK inhibitors, DNA repair inhibitors, and replication stress inducers may all affect MCM expression, MCM chromatin binding, or CMG formation. After drug treatment, if MCM decreases, EdU decreases, and cells remain in G1 phase, replication licensing may be inhibited. If MCM remains high while γH2AX and p-Chk1 (Ser317/Ser345) increase, replication fork stress and DNA damage accumulation should be considered. If MCM remains unchanged but PCNA or EdU decreases, further assessment is needed to determine whether replication elongation is blocked.

5.3 Tissue IHC and Interpretation Boundaries

In tissue samples, MCM proteins usually show nuclear-positive signals. Increased MCM positivity in tumor parenchymal areas may indicate an increased number of cells within the proliferative cycle or with replication potential, but routine IHC cannot directly demonstrate active replication licensing. However, necrotic margins, reparative proliferative regions, normal high-turnover epithelium, and activated immune cells may also show MCM positivity. Therefore, IHC results should be interpreted together with tissue architecture, pathological morphology, Ki-67, PCNA, and tumor lineage markers. MCM positivity alone should not be used to infer tumor invasiveness, metastatic capacity, or prognosis.

6 Interpretation Pathway for MCM Detection Results

6.1 Total MCM, Chromatin-Bound MCM, and Active CMG

MCM detection should not only observe total protein expression. Increased total MCM usually indicates that cells have a higher MCM protein reserve. Chromatin-bound MCM is closer to replication origin licensing. The simultaneous presence of MCM with CDC45 and GINS is closer to CMG formation and replication origin activation. If the experimental goal is to assess replication licensing, chromatin-bound MCM should be prioritized. If the goal is to assess DNA synthesis, EdU, PCNA, and DNA content should be combined. If the goal is to assess replication stress, RPA, p-Chk1 (Ser317/Ser345), and γH2AX should be included.

6.2 Interpretation of Increased, Decreased, and Unchanged MCM

Increased MCM does not necessarily represent enhanced cell proliferation. It may also reflect increased replication licensing reserve, enhanced G1/S preparation, or compensation under replication stress. Decreased MCM usually suggests reduced replication licensing capacity. However, if Ki-67 also decreases and the G1-phase proportion increases, it is more likely that cells have exited proliferation or undergone G1/S arrest. If MCM remains unchanged while EdU decreases, licensing proteins are still present, but replication origin activation, replication elongation, or checkpoint regulation may be impaired.

6.3 Recombinant MCM Proteins and Methodological Validation

Recombinant MCM proteins are mainly used for antibody validation, WB positive controls, ELISA coating, protein interaction studies, and method development. They address whether the detection system can recognize the target MCM protein. They cannot replace intracellular MCM2-7 complexes and cannot represent complete CMG helicase activity. Taking Recombinant Human MCM5 Protein as an example, its reasonable applications include validating MCM5 antibody recognition, establishing human MCM5 detection systems, or performing in vitro binding experiments, rather than independently evaluating DNA replication helicase function.

7 Common Questions and Result Interpretation

7.1 MCM Protein Elevation and Tumor Malignancy

Elevated MCM protein expression mainly indicates increased proliferative or replication potential, but cannot independently demonstrate enhanced replication licensing, tumor malignancy, metastatic capacity, or treatment resistance. A more cautious approach is to combine Ki-67, PCNA, EdU, γH2AX, cell cycle status, and histopathological background to distinguish enhanced replication licensing, genuine enhancement of DNA synthesis, and increased replication stress.

7.2 Substitution Relationship Among MCM5, MCM2, and MCM7

MCM2, MCM5, and MCM7 are all members of the MCM2-7 complex, but their detection performance may differ depending on antibody, cell type, and experimental condition. Selecting one or two MCM members for joint validation according to the research question is more reliable than using a single member as the only representative of the entire complex. If only MCM5 is detected, the result interpretation should state that it represents changes in an MCM family member rather than complete complex activity.

7.3 Increased MCM Protein with EdU-Negative Results

Increased total MCM protein without increased EdU indicates increased MCM expression without a corresponding increase in DNA synthesis; whether replication licensing is enhanced requires assessment of chromatin-bound MCM2-7. It may also occur in G1/S arrest, restricted replication origin activation, or early replication stress. In this case, DNA content, Cyclin E/CDK2, p21, PCNA, CDC45/GINS, and γH2AX should be evaluated to determine whether the problem occurs at the licensing stage, origin activation stage, or replication elongation stage.

7.4 Recombinant MCM Proteins and Complete Helicase Activity

Complete replicative helicase function depends on the CMG complex jointly formed by MCM2-7, CDC45, and GINS. A single recombinant MCM protein is more suitable for antibody validation, ELISA coating, protein interaction studies, and method development, but is not suitable as a substitute system for complete helicase activity experiments. If the research goal is replication fork progression or helicase function, cell models, complex detection, or functional assays closer to the replication system should be selected.

8 Product Selection Related to MCM Protein Family Research

The MCM protein family is suitable for analyzing DNA replication licensing, replication stress, cell cycle progression, and tumor proliferation status. In experiments, MCM indicators should be interpreted together with EdU, PCNA, Ki-67, γH2AX, and cell cycle proteins, avoiding overinterpretation of changes in a single MCM member as complete replication function or tumor-specific conclusions.

For more related articles, please see below:

[1] DNA Damage and Repair

[2] Flow cytometry cell cycle analysis using propidium iodide DNA staining